Esperion Therapeutics (ESPR) Stock Price, News & Analysis

Company Overview

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Key Stats

• Today's Range: $1.74 to $1.88
• 50-Day Range: $1.79 to $3.83
• 52-Week Range: $1.58 to $3.94
• Volume: 3.95 million shs
• Average Volume: 5.19 million shs
• Market Capitalization: $370.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.25
• Consensus Rating: Moderate Buy

Esperion Therapeutics Stock Analysis - MarketRank™

Esperion Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 205th out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Esperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Esperion Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Esperion Therapeutics is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Esperion Therapeutics is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.42% of the float of Esperion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Esperion Therapeutics has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Esperion Therapeutics has recently increased by 5.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Esperion Therapeutics does not currently pay a dividend.

Dividend Growth

Esperion Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.76

Percentage of Shares Shorted

17.42% of the float of Esperion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Esperion Therapeutics has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Esperion Therapeutics has recently increased by 5.04%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: -0.50

News Sentiment

Esperion Therapeutics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Esperion Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 26 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.

MarketBeat Follows

12 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20.00 in company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Esperion Therapeutics is held by insiders.

Percentage Held by Institutions

47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ESPR Stock Analysis - Frequently Asked Questions

How have ESPR shares performed this year?

Esperion Therapeutics' stock was trading at $2.20 at the start of the year. Since then, ESPR shares have decreased by 14.5% and is now trading at $1.88.
View the best growth stocks for 2025 here.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.01. The biopharmaceutical company had revenue of $51.63 million for the quarter, compared to analyst estimates of $55.44 million.

Who are Esperion Therapeutics' major shareholders?

Top institutional shareholders of Esperion Therapeutics include Sigma Planning Corp (0.10%), Summit Wealth Group LLC (0.08%), SG Americas Securities LLC (0.08%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Sheldon L Koenig, Benjamin Halladay, Eric Warren, Joanne M Foody, Benjamin Looker and J Martin Carroll.
View institutional ownership trends.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AUO (AUOTY).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/04/2025
• Next Earnings (Estimated): 2/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ESPR
• CUSIP: N/A
• CIK: 1434868
• Web: www.esperion.com
• Phone: (734) 887-3903
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.25
• High Stock Price Target: $16.00
• Low Stock Price Target: $2.50
• Potential Upside/Downside: +285.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-209,250,000.00
• Net Margins: -29.37%
• Pretax Margin: -29.37%
• Return on Equity: N/A
• Return on Assets: -10.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.85
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $116.33 million
• Price / Sales: 3.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.85) per share
• Price / Book: -0.49

Miscellaneous

• Outstanding Shares: 197,040,000
• Free Float: 195,065,000
• Market Cap: $370.44 million
• Optionable: Optionable
• Beta: 1.01